NEW ORLEANS--(BUSINESS WIRE)--Kahn Swick & Foti, LLC ("KSF") and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until November 4, 2014 to file lead plaintiff applications in a securities class action lawsuit against Enzymotec Ltd. (Nasdaq: ENZY), if they purchased the Company’s securities in connection with the Company’s initial public offering (“IPO”) on or about September 27, 2013, and/or on the open market between September 27, 2013 and August 4, 2014, inclusive (the “Class Period”). This action is pending in the United States District Court for the District of New Jersey.
What You May Do
If you purchased shares of Enzymotec and would like to discuss your legal rights and how this case might affect you and your right to recover for your economic loss, you may, without obligation or cost to you, call toll-free at 1-877-515-1850 or email KSF Managing Partner Lewis Kahn (email@example.com). If you wish to serve as a lead plaintiff in this class action, you must petition the Court by November 4, 2014.
About the Lawsuit
Enzymotec and certain of its executives are charged with issuing a series of materially false and misleading statements in connection with its IPO and during the Class Period, violating federal securities laws.
These false statements and omissions included, in part, that: (i) Enzymotec’s Chinese business was subject to material and readily identifiable compliance regulations from the Chinese government; (ii) Enzymotec’s baby formula business in China was jeopardized and subject to increased volatility and decreased revenues; and (iii) Enzymotec’s joint venture with AarhusKarlshamn AB, which marketed the popular InFat product, was crumbling and subjected the Company to liability and decreased revenues.
About Kahn Swick & Foti, LLC
To learn more about KSF, whose partners include the Former Louisiana Attorney General, Charles C. Foti, Jr., and other lawyers with significant experience litigating complex securities class actions nationwide on behalf of both institutional and individual shareholders, you may visit www.ksfcounsel.com.